Business Wire

iBASIS Integrates Cutting Edge Multi-Protocol Signaling Firewall of Security Expert jtendo for Global Cloud-Based Network Protection

19.9.2022 08:00:00 EEST | Business Wire | Press release

Share

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, today announced the integration of the cutting-edge multi-protocol signaling firewall of telecom security expert jtendo to its Managed Cloud-Based Security Portfolio, iBASIS Security iQ360.

The increase in the number of network protocols (also covering 5G), technologies, and roaming traffic creates a greater complexity requiring advanced features for testing and cross-protocol correlation to monitor, analyze, detect, and prevent security breaches. The strategic partnership combines jtendo security audit experience, deep technical knowledge of telco protocols, and cross-protocol correlation expertise with iBASIS’ unique international and managed cloud-based skills, with dedicated security centers in Americas, Europe, and Asia.

"The growing threat trend around today’s telecom networks drives the need for innovative security management solutions that can adapt quickly to new threats," says Guillaume Klein, iBASIS Vice President, Product Management. "We are thrilled to collaborate with jtendo to achieve effective threat management and be able to leverage their unique auditing and multiprotocol expertise to raise the level of protection even further."

"We are very proud to partner with one of the largest international signaling, voice, and data networks and complement iBASIS’ 360-degree intelligence-based solution," adds Piotr Szymański, jtendo CEO. "Mobile operators are increasingly searching for threat management that continuously adapts to their ever-changing network landscape, offering a flexible managed solution hosted on the IPX network is an effective way to secure their signaling network as an ongoing process. We are always there to support our customers in keeping their network safe in all areas."

The iBASIS Security iQ360 platform provides MNOs with a high level of process automation to assess vulnerability and address security risks with advanced auditing. The solution relies on in-depth visibility, monitoring, and attack detection complemented with automatic rule updates against continuously evolving threats.

iBASIS and jtendo will be part of WAS#16, September 19-22, in Cape Town and will jointly present real-world security cases at Stand# L10.

ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 800+ LTE destinations.

iBASIS optimizes global connectivity, quality and security, so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, IoT and cloud communications to be first in their respective markets. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.

ABOUT JTENDO
jtendo is the expert in telecom security, providing high-quality solutions and services to mobile network operators in more than 30 countries. jtendo secures networks against SS7, Diameter, and GTP vulnerabilities through a security suite headed by its proprietary SigWall (jtendo Signaling Firewall) solution.

With 90,000 TPS per single site in the largest SigWall installation, more than 1 million total TPS across all platforms and more than 100 million subscribers served by its platforms, jtendo is one of the world's most sought-after telecom and security specialists.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Melissa Coffman
26FIVE Tech Lab
+1 202 251 1793
iBASIS@26FIVE.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye